AA
XPH icon

AlphaMark Advisors’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History

AlphaMark Advisors’s Portfolio XPH Stock Details XPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		$285K Buy
6,640
+415
+7% +$18.9K 0.12% 104
2024
Q3 		$276K Buy
6,225
+348
+6% +$14.9K 0.1% 206
2024
Q2 		$234K Buy
+5,877
New +$238K 0.08% 217

Other funds holding XPH

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KWM
Kingsview Wealth Management Grants Pass, Oregon $7.33B AUM 16.07% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
Envestnet Portfolio Solutions
Envestnet Portfolio Solutions Chicago, Illinois $20.9B AUM 19.34% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AlphaMark Advisors's XPH Position: Q4 2024 in Review

AlphaMark Advisors increased its State Street SPDR S&P Pharmaceuticals ETF (XPH) stake by 6.7% in Q4 2024, buying an estimated $18.9K and bringing the position to 6,640 shares worth $285K. The position accounts for 0.12% of the portfolio, ranked #104.

AlphaMark Advisors first reported a position in XPH in Q2 2024 and has held it in 3 quarters since. 73 funds tracked by Wall St. Rank hold XPH as of Q4 2024.

  • AlphaMark Advisors held 6,640 shares of State Street SPDR S&P Pharmaceuticals ETF worth $285K as of Q4 2024.
  • AlphaMark Advisors bought 415 State Street SPDR S&P Pharmaceuticals ETF shares in Q4 2024, an estimated $18.9K.
  • State Street SPDR S&P Pharmaceuticals ETF made up 0.12% of AlphaMark Advisors's portfolio in Q4 2024, its #104 holding.
  • AlphaMark Advisors first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q2 2024 and has held it in 3 quarters since.
  • 73 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q4 2024.

Based on AlphaMark Advisors's 13F filing for Q4 2024, filed 21 Jan 2025.